Further thoughts on 'cell kill' in acute leukemia.

Abstract

With traditional therapy of acute myelogenous leukemia, not more than 20% of patients achieve long-term survival. Efforts at intensifying postinduction chemotherapy have resulted in minor improvements only, but this limited progress has been hampered by increasing toxic-death rates. Eradication of the leukemia burden may be achieved by the introduction of… (More)

Topics

  • Presentations referencing similar topics